Literature DB >> 3262691

Ro(SS-A) positive Sjogren's/lupus erythematosus (SC/LE) overlap patients are associated with the HLA-DR3 and/or DRw6 phenotypes.

T T Provost1, N Talal, W Bias, J B Harley, M Reichlin, E L Alexander.   

Abstract

Ro(SS-A) positive female Sjögren's syndrome (SS) lupus erythematosus (LE) overlap patients are a clinically and serologically homogeneous group generally demonstrating prominent subacute cutaneous lupus erythematosus (SCLE) lesions, cutaneous vasculitis, peripheral and central nervous system disease, pulmonary disease, and a low frequency of glomerulonephritis. They commonly demonstrate rheumatoid factor, hypergammaglobulinemia, antinuclear and Ro(SS-A) La(SS-B) antibody activity. This study indicates that these patients are also immunogenetically similar, sharing a statistically significant increased frequency of HLA-B8, DR3, DRW6, DQ2, and DRw52. Sixty-three percent of these SS/LE patients possess the extended haplotype (P-value 6.0 X 10(-3); RR 9.5) HLA-B8, DR3, DQ2, DRw52. One hundred percent of this SS/LE cohort was DR3 or DRw6 (P-value less than or equal to 5.0 X 10(-3); relative risk 19.1). Fifty percent of these patients were HLA DR3/DRw6 heterozygotes (P-value 1.5 X 10(-6); relative risk 31.2). Thus, HLA-DR3 and DRw6 Ro(SS-A) positive SS/LE patients may possess a similar, if not unique, DR region DNA nucleotide sequence involved in disease susceptibility or immune regulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262691     DOI: 10.1111/1523-1747.ep12476204

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group.

Authors:  K Hartung; H Ehrfeld; H J Lakomek; R Coldewey; B Lang; F Krapf; R Müller; D Schendel; H Deicher; H P Seelig
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

2.  Immunoglobulin allotypes are not associated with HLA-antigens, autoantibodies and clinical symptoms in systemic lupus erythematosus. Members of the SLE Study Group.

Authors:  K Hartung; R Coldewey; E Röther; K Pirner; C Specker; D Schendel; W Stangel; S Stannat-Kiessling; G G de Lange
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  MHC associations of autoantibodies against recombinant Ro and La proteins in systemic lupus erythematosus. Results of a multicenter study. SLE Study Group.

Authors:  H Ehrfeld; K Hartung; M Renz; R Coldewey; H Deicher; M Fricke; J R Kalden; J Lakomek; H H Peter; D Schendel
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

4.  Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.

Authors:  Siavash Nasiri; Mansoor Karimifar; Zahra Sayed Bonakdar; Mansour Salesi
Journal:  Rheumatol Int       Date:  2009-10-07       Impact factor: 2.631

5.  British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2007-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.